Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089993 | 0.96 | PPARG (0.34) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089911 | 0.94 | CNR1 (0.35) | WDR5PPARGDGAT2 | |
| SCHEMBL10089893 | 0.94 | PPARG (0.37) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089968 | 0.94 | PTGER4 (0.35) | WDR5PPARGPTGER4PTGDRDGAT2 | |
| SCHEMBL10089860 | 0.94 | PTGER4 (0.35) | WDR5PPARGPTGER4PTGDRDGAT2 | |
| SCHEMBL10090016 | 0.94 | PTGER4 (0.35) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089961 | 0.94 | WDR5 (0.34) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089884 | 0.93 | WDR5 (0.36) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089877 | 0.93 | PTGER4 (0.35) | WDR5PPARGPTGER4PTGDRDHODH | |
| SCHEMBL10089927 | 0.92 | WDR5 (0.37) | WDR5PPARGPTGER4PTGDRDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582695-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES WITH CYCLICAL SIDE CHAINS | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | WDR5 2893/4885KCNB1 1400/4885KCNA5 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.